Under Pressure, CMS Backs Off New Part D Protected Class Management
Decision in final rule marks a setback in the Trump Administration’s game plan for lowering drug prices. But CMS proceeds with codifying previous guidance allowing step therapy for Part B drugs in Medicare Advantage.
